Enterovirus A vaccine - Beijing Vigoo Biological

Drug Profile

Enterovirus A vaccine - Beijing Vigoo Biological

Alternative Names: EV71 vaccine- Beijing Vigoo Biological; HFMD vaccine - Beijing Vigoo Biological; Vero cell-based vaccine - Beijing Vigoo Biological

Latest Information Update: 17 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Beijing Vigoo Biological
  • Developer Beijing Vigoo Biological; Jiangsu Provincial Center for Disease Control and Prevention
  • Class Enterovirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Enterovirus A infections

Most Recent Events

  • 17 May 2015 No development reported - Phase-III for Enterovirus A infections (Prevention) in China (Parenteral)
  • 01 May 2013 Beijing Vigoo Biological completes a phase II trial for Enterovirus A infections (Prevention) in China (NCT01679665)
  • 14 Mar 2013 Beijing Vigoo Biological completes a phase III trial for Enterovirus A infections (Prevention) in China (NCT01508247)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top